X-ray equipment scrutinised by Blue Shield
This article was originally published in Clinica
Blue Shield is conducting a survey of X-ray equipment and radiology procedures used by Pennsylvania healthcare providers. The first in a series of quality reviews of medical procedures planned by Blue Cross under its Quality Based Health Care Management (QBM) programme, the review is being undertaken following reports of serious deficiencies in the quality of X- rays by some providers in the State. Blue Shield reimbursed almost 3,400 providers in Pennsylvania over $163 million in 1994 for X-ray procedures.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.